<SEC-DOCUMENT>0001193125-13-076186.txt : 20130226
<SEC-HEADER>0001193125-13-076186.hdr.sgml : 20130226
<ACCEPTANCE-DATETIME>20130226133411
ACCESSION NUMBER:		0001193125-13-076186
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130220
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130226
DATE AS OF CHANGE:		20130226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESMED INC
		CENTRAL INDEX KEY:			0000943819
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980152841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15317
		FILM NUMBER:		13641927

	BUSINESS ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		8587462400

	MAIL ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d491348d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>February&nbsp;20, 2013 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ResMed Inc.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-15317</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>98-0152841</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation) </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number) </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9001 Spectrum Center Boulevard </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>San Diego, California 92123 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(858) 836-5000
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02(b),&nbsp;(c),&nbsp;(d).&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Appointment of
Chief Executive Officer, Director and Executive Chairman </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;20, 2013, the Board of Directors (the
&#147;Board&#148;) of ResMed Inc. (the &#147;Company&#148;) approved the appointment of Michael Farrell, age 40, as the Company&#146;s chief executive officer, to be effective March&nbsp;1, 2013. Mr.&nbsp;Farrell has served as the Company&#146;s
president &#150; Americas since May 2011. He was previously our senior vice president, strategic business unit &#150; sleep from July 2007 to May 2011, and before that role he was our vice president, marketing for the Americas from June 2005 through
July 2007, and our vice president, business development. Before joining the Company in September 2000, Mr.&nbsp;Farrell worked in management consulting and biotechnology, as well as in chemicals and steel manufacturing at Arthur D. Little, Genzyme
Corporation, The Dow Chemical Company, and BHP Billiton. Mr.&nbsp;Farrell sits on the board of directors of the American Association for Homecare, the Museum of Photographic Arts, San Diego, and the New Children&#146;s Museum, San Diego.
Mr.&nbsp;Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of
Management. In addition to his appointment as chief executive officer, Mr.&nbsp;Farrell was appointed to serve as a director on the Board effective as of March&nbsp;1, 2013. At this time, we do not expect Mr.&nbsp;Farrell to serve on any of the
Board&#146;s committees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;20, 2013, and in connection with the appointment of Michael Farrell as the
Company&#146;s chief executive officer, the Board determined that Peter Farrell, the current chairman of the Board, president, and chief executive officer of the Company, will serve solely as executive chairman of the Board effective as of
March&nbsp;1, 2013. As executive chairman, Dr.&nbsp;Farrell will remain an executive officer and employee of the Company with responsibility for advising senior management with respect to the strategy, management and operations of the Company. At
this time, we expect Dr.&nbsp;Farrell to transition to non-executive chairman of the board as of January&nbsp;1, 2014, when he will no longer be an executive officer or employee of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The compensation arrangements in connection with Michael Farrell&#146;s service as the Company&#146;s chief executive officer have not
yet been determined. Mr.&nbsp;Farrell will not be entitled to additional compensation for his service as a director. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
compensation arrangements in connection with Peter Farrell&#146;s service as executive chairman have also not yet been determined. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Michael Farrell is the son of Peter Farrell.&nbsp;During the first two quarters of the current fiscal year, the Company made sales in the amount of US $<U></U>1,451,332 to ResSleep Pty Ltd.&nbsp;ResSleep
Pty Ltd. is an Australian customer of the Company that is owned by Paul Farrell, son of Peter Farrell and brother of Michael Farrell. Paul Farrell is chairman and chief executive officer of ResSleep Pty Ltd.&nbsp;Sales transactions between ResSleep
Pty Ltd. and the Company&#146;s Australian sales subsidiary are managed independently by the Company&#146;s president &#150; Asia Pacific. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Management Appointments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;20, 2013, the Board determined that the Company&#146;s current chief operating officer, Robert Douglas, age 53, will also serve as the Company&#146;s president, effective as of
March&nbsp;1, 2013. Mr.&nbsp;Douglas has served as our chief operating officer since September 2011, and his former roles with the Company include president &#150; Asia Pacific and chief, global supply operations from May 2011 thru September 2008,
responsible for global manufacturing and commercial distribution and sales operations in the Asia Pacific region; chief operating officer &#150; Asia Pacific from July 2008 through May 2011; chief operating officer &#150; Sydney from 2005 through
July 2008, responsible for the Company&#146;s manufacturing and research and development; vice president of operations from 2003 - 2005 responsible for the Company&#146;s manufacturing; and vice president of bilevel division from 2000 &#150; 2003.
Mr.&nbsp;Douglas first joined the Company in 2001 in the role of vice president of corporate marketing. Mr.&nbsp;Douglas has a master of business administration from Macquarie University, a bachelor&#146;s degree in electrical engineering with
first-class honors and a B.Sc. (computer sciences) from the University of New South Wales, Sydney. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The compensation
arrangements in connection with Mr.&nbsp;Douglas&#146; service as president and chief operating officer have not yet been determined. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Douglas is not a party to any transaction with the Company or any subsidiary of the Company and has no family relationships with any member of the Board or any other executive officer of the
Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;20, 2013, the Board approved the appointment of Jim Hollingshead, age 49, to succeed Michael
Farrell as the Company&#146;s president &#150; Americas, effective March&nbsp;1, 2013. Mr.&nbsp;Hollingshead joined the Company in March 2010 as vice president of strategy and business development. In August 2011, his role was expanded to include
the leadership of ResMed ventures and initiatives, the unit within the Company responsible for growing early stage businesses. Before joining the Company, Mr.&nbsp;Hollingshead spent 18 years in strategy consulting, where he worked with senior
executives across a wide range of industries. From September 2008 to February 2010, he was a senior partner in the strategy and life sciences practices in Deloitte Consulting, based in San Francisco. Before that Mr.&nbsp;Hollingshead was managing
partner, west coast for Monitor Group, a leading global strategy consulting firm. While at Monitor Group, Mr.&nbsp;Hollingshead worked in various offices around the world, and successfully launched and ran three different practices, including a
pan-European marketing strategy practice based in London. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
February&nbsp;20, 2013, the Company issued a press release announcing the management transition changes described under Item&nbsp;5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated here by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:31pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Document</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated February 20, 2013</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: February&nbsp;26, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESMED INC.</B></FONT></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ David Pendarvis</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Pendarvis</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief administrative officer, global general counsel and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">secretary</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:31pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description of Document</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated February 20, 2013</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d491348dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g491348image.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESMED APPOINTS MICHAEL FARRELL AS CHIEF EXECUTIVE OFFICER; </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ROBERT DOUGLAS APPOINTED PRESIDENT AND CHIEF OPERATING OFFICER </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">San Diego, California, Feb. 20, 2013 - ResMed Inc. (NYSE: RMD) announced today that effective March 1, 2013, Michael (&#147;Mick&#148;) Farrell will succeed Dr. Peter C. Farrell as ResMed&#146;s chief
executive officer (CEO) and be appointed to its board of directors. Robert (&#147;Rob&#148;) Douglas will become ResMed&#146;s president and chief operating officer (COO). Current CEO, chairman of the board and founder, Dr. Farrell, will become
executive chairman. Together, Mr. Farrell and Mr. Douglas will comprise the office of the CEO and Dr. Farrell will work together with them on an as-needed basis through the end of calendar year 2013, when he will transition to non-executive
chairman. In addition, Dr. Jim Hollingshead has been named president, Americas. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;A thorough review of potential candidates to succeed
Peter was conducted by the board&#146;s CEO succession committee, working closely with the nominating and governance committee and a top-tier executive search consultancy,&#148; commented Dr. Gary Pace, lead director of ResMed&#146;s board and
chairman of the board&#146;s succession committee. &#147;It was easily determined that members of the very talented and experienced team that have driven much of the company&#146;s great success over the past decade would be best suited to lead the
company to its next stages of growth and development. Mick led the team in the Americas that grew sales over 30 percent during the seven quarters that he was president of that region. He also established a vision for the organization that extended
beyond driving revenue and market share to include a focus on the number of lives enhanced by ResMed products. Mick&#146;s strengths and accomplishments leading sales, marketing, business development and commercial strategy teams equip him well to
become ResMed&#146;s next CEO. Rob&#146;s expertise and excellent track record of increasing productivity and efficiencies of global operations, as well as success in growing sales, make him the ideal choice for COO and president. In addition, he
was instrumental in creating our successful manufacturing presence in both Australia and Singapore. At this time, we also want to thank Peter for resuming the role of CEO over the past couple of years and now turning over the helm to Mick and Rob
while staying on as executive chairman of the board.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;I have little doubt that Mick and Rob will build on ResMed&#146;s momentum
as a global driving force in sleep and respiratory medicine, and as a leader in the medical device industry,&#148; said Dr. Peter Farrell. &#147;Mick has been with us for more than 12 years; Rob for more than 11. This is a deeply experienced and
accomplished duo to lead ResMed. They have also played an integral role in developing and preserving the unique culture established within ResMed which has proved to be an extremely important component of the success of the company. The board and I
are extremely confident in the ability of our senior management, as well as the talent at all levels throughout ResMed.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Rob and I
have worked in collaboration with the entire organization at ResMed for more than a decade to help drive the success of our core business by producing the best products on the market, becoming the preferred mask brand by patients and promoting the
awareness of sleep-disordered breathing,&#148; commented Mick Farrell. &#147;I am extremely excited to be taking the reins of a company that will contribute to the well-being and improved quality of life of millions of patients suffering from
sleep-disordered breathing. Looking forward, we have huge opportunities to leverage current ResMed offerings and our product pipeline to change the lives of millions of patients who suffer from such co-morbidities as congestive heart failure and
chronic obstructive pulmonary disease. Our future success will be accelerated by ResMed&#146;s intense focus on innovation, breaking down barriers to diagnosis and treatment, and an emphasis on our culture, which attracts world-class talent who
learn to share our passion for changing lives, one breath at a time.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;I am looking forward to working together with Mick and the rest of the team to build on the success
and achievements of ResMed,&#148; said Rob Douglas. &#147;We are uniquely positioned in healthcare. We improve patients&#146; quality of life, slow down and even improve other medical co-morbidities, and reduce the cost of healthcare. I am confident
we will continue to succeed in the future.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>About Mick Farrell </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael &#147;Mick&#148; Farrell, joined ResMed in 2000 and became president, Americas in 2011, responsible for Americas sales and
commercial operations. Previously, Mick was senior vice president, sleep strategic business unit from 2007 to 2011, where he led the global team that executed the design, development and launch of the very successful S9<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> platform of flow generator products. Before that, he held the positions of vice president, marketing for the
Americas and vice president, business development. Before joining ResMed, Mick worked in management consulting and biotechnology, as well as in chemicals and steel manufacturing at Arthur D. Little, Genzyme Corporation, The Dow Chemical Company and
BHP Billiton. Mick holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology (MIT) and an M.B.A. from the MIT Sloan
School of Management. He sits on the board of directors of the American Association for Homecare. Mick is the son of Dr. Peter Farrell. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>About Rob Douglas </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rob Douglas, as chief operating officer, holds full operational
responsibility for ResMed and its subsidiaries and is also now being appointed as president. He joined ResMed in 2001 as vice president of corporate marketing and has since excelled in additional ResMed roles including president &#150; Asia Pacific
and chief, global supply operations, responsible for global manufacturing and commercial distribution and sales operations in the Asia Pacific region; COO &#150; Asia Pacific, and COO &#150; Sydney. Before joining ResMed, Rob had various roles at
Keycorp, an Australian electronics commerce company, managing strategy and new business, marketing and research and development. Prior to that, he was head of operations, project management and engineering at Telectronics Pty Ltd., an Australian
medical electronics company. Rob has a master&#146;s of business administration from Macquarie University, a bachelor&#146;s degree in electrical engineering with first-class honors and a bachelor of science (computer sciences) from the University
of New South Wales. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Jim Hollingshead Becomes President, Americas </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As Mick Farrell transitions to the CEO role, current ResMed chief strategy officer and president, ventures &amp; initiatives strategic business unit, Jim
Hollingshead, will replace Farrell as president, Americas. Jim joined ResMed in 2010 as vice president of strategy &amp; business development. In 2011 his role was expanded to include leadership of ResMed ventures &amp; initiatives, the unit within
ResMed responsible for growing early stage businesses. Before ResMed, Jim spent 18 years in strategy consulting, where he worked across a wide range of industries, with senior roles at Deloitte Consulting and Monitor Group. Jim holds a bachelor of
arts degree in history and international relations with distinction from Stanford University, and an MA and PhD in political science from the University of California at Berkeley, where he was awarded a prestigious graduate student fellowship by the
National Science Foundation. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contacts:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For news media:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the financial and investment community:</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gretchen Griswold</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Constance Bienfait</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dir., Global Corporate Communications</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, Investor Relations</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(858) 836-6789</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(858) 836-5971</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brett Sandercock</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">+61(2) 8884-2090</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ResMed is a global leader in the development, manufacturing and marketing of medical products for the
diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing
awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Statements contained in this release that are not historical facts are &#147;forward-looking&#148; statements as contemplated by the Private Securities
Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the company&#146;s future revenue, earnings or expenses, new product development and new markets for the company&#146;s products, are subject to risks
and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the company&#146;s Annual Report on Form 10-K for its most
recent fiscal year and in other reports the company files with the U.S. Securities &amp; Exchange Commission. Those reports are available on the company&#146;s website. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g491348image.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491348image.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@",`P$1``(1`0,1`?_$`*L```$#!`,!````````
M```````&"0H!!`<(`@4+`P$``00#`0$```````````````0&!P@!`P4""1``
M``8!!`$"!`('"`,``````0(#!`4&!P`1"`D2(1,Q(A0*019187&A(R05\,'Q
M,M255A="4AH1``(!`P,#`@0$!`4"!P$```$"`Q$$!0`A!C$2!T$346%Q(I$R
M%`B!T5(CH<&"DA6Q8O#Q0G*B,R08_]H`#`,!``(1`Q$`/P"?QHT:IOMKRS!>
MOKHU3R`?\!UDM3XZ\AU.J^0:QWBH&]3KUUZ:`$!#<->M&JZ-&C1HT:-&J".P
M;C^K]X[:-8)IUU3S+OMOZ^@^@#\!^`_NU@LJ_F('U.LFH%:&E=`G`/CO^GX#
MZ?M_1K#.%^/2NV_X?'1Z=QV'ST>9?[`.@N@%6('U(T>M-_\`+\=5`0'X:]?,
M=-&JZ-&C1HT:-&C1HT:-&J".VL$TT:BZ?<6]B/('B(_XR8VXU99F\4VVV,\B
MW^^R4$VA'3M[5HQ2$KU79."3,7*D29K2RL@KN0I3&,W#U$"B`V2_;]P3!<MB
MR61Y%:)<6,)C1"Y8=C#N,AHO78IJ"O-'-,QQ9K"TP<YANIA(7H`:BJ!!OT->
M_P"6FXJI_P#4-=JS6[E69[-DA7+9!1%FK\@>>XZM!?PD\P;RD2],S?KM7S7Z
MI@Z34]I9--4GEL<I3`(!(5W-^V>UN'M)4M!<Q2-&R]MR?N0T)J$*T^!KOID1
MR>>YX5N(3,T+HK`CV]PPJ-COT^6D#B[NH[4.#?)F+Q'SD<2MWB8VRUYIE3&>
M4:G5HR[1=6L)V@A8Z7<:@R8$.LG%.OK61Q4?QCPI/`0`1$Y.CE?#?C3F_%CF
M^#M'#<-&YADB=S&6C'<R2*^X;T.U17J-),;Y/\@<5Y&,3RX>XK,H*2!0:-T9
M&4?YT^NVIYPST.W;M%W<HQ:)/42N&BCQTW9@Y14(14JB(.%$C'`"*EWV#<-_
M75'8;>Y=FB5'9T)!(%?4^BUI_&E=6R:>!$5Y'10PJ*FE?I77#\SUK_D,'_NT
M?_J-;?TMR.L<E?\`VG^6L"X@.X=:?4?SUV#=^S>(E<LW"+QN<3`1=HLDY14$
MIA(8"*(G.0PE,&P[#Z#K6Z-$:2@J?F"#^!WWUL1ED%8R"/D1_P!:T_QT@5,R
MXC1GORJME''25H]\&H5M2\U4D\+D1\0;A#FE@D??$?\`P]OR_5I6,7E6C,RV
MMR8:`]WMMVT/SIZ?.FD?_)XXR>T)X2_P]Q*_A6O^&EQ)2C*+CI"4D5BM(^+9
MNI"0<K"!4VS)B@=TZ75-O\I$FZ1C"/X`&D$:BY;VD^YRP6GK4F@&EK,(HS-)
MLB@D_0>NO-@R9W5]FMEN^6[C0>4N0Z_CT]VL\C78F,AZ8I&5*LSUBEQI4.19
MS5EEBI(Q9$T414.<QQ2-N([".OHQC_"WCZ#&6EGD<=;/D6ME1G!8,9EC#LW7
M\N^_K7:FJ39#RCS:;(7,]A>2+CTN-A\$9J`>NO07P'E+ZOB#A;-.3K&F(.>.
M./,FY"MTB=%%$14QK$6BUV)^<A$4$R"/U#A42E*4/78`#TU03.8MH>576&L$
MJPOI(8D'I20HH'Q]*5U;S$9'W..VV4OV':UFDDC'IN@8D_X_QU`2Y$=Y78E=
MLN9*R3BCD%?L7X:M]YMBV(Z5'1%2_I\/3(AVFRA6"*TC6GC]V]+'`W5>G.H;
M^<<'`-O\H7RX[X1X!C\1:VV8LK>ZRL$"?J68L>Z1A5J;B@H05VZ'H-5'S_EG
MFLV4:;%W+V^,DD/MJ`#]H:G4UZ?([T.I\W$I[>H3BQQX#.]Z5M&6)'$5&EK_
M`&FRK1<=)S-OF:^PF9\[A%!*.9E49OY`R'BBD4I2I@&VJ(\H_1S\JR"X2W]K
M&+=R+'&@)"HA[1T)V:E1]=]6]PLUPF&M&RDJM>O`K.QHM2PKTKZ5H=;"?FBM
M?\A@_P#=H_\`U&N,;2['6&;_`&-_+73%Q`VZNA'R8?SU<C-1!6H/QDF'T(CX
M@]^M:@S$WGX>(.A6!#R\_3;RWWUJ,<HD]GL?WZ5[>T]WX4KKT94$9EJ/:!ZU
M%/QKJW+9JX<0`L]#&$1`-BRC`1W,(`4-@<#ZB([!KW^GO*T$$YK_`-C?RUCW
MX*5[T_W#^>NZ`Y1^'ZOW_`?V#K1W"M-Z_A3ZUUMZBOH=<M>M&N!Q$``0#?U_
MN'7AZ[4V^X?AZZP=M_\`Q\->=;]PKF2%RCVDVVOR3AR^J&#JABG%<FDP,BHX
M*@FC^?;PW8$753;!(&4NBK8@*&(05DB@80#<=?0+]O\`@KBR\8*]LC?K[QYI
M.[<**@QIW4#;$*K#^.J9^9LG!=>0!'/W-:6RQJRJ17^HT^>YT].P^Z:X;04&
MQ@J[QHY%"C#Q32*A8TZ^*6:(-(UHFR8M142NCD6R2;=`I=RI'`H!Z`/PU#O_
M`/,',;B5Y;K)6"M(Q9V_N%@2=V[2B]WX_74H#SWQBT@6.*TO##&BJ*T`%!L*
M_P">^FO<#89RWW[=DMDY2V2&K6,<`46SX['($)^;8F8L<+CRC(MU*ECB*A_<
M1L$S-W?Z!47\N+%M$MS.7(D.)TTT#2+G\OB_!?C>'A\$DUUGYHY3'($[$[Y?
MM>2NZ]O]*U[A2G0U#%PMG?\`E_G+<GN(TBPMNZ[5!;M3<"FQ)-*5IU)/IK8[
MOYFJ]R([0N'?$2=R*QQC0*S4*I'9#O$C+QT)!8_0RY<%Y"QV)X[EW+2%:*0U
M#J[19'ZHP)&,H0@CL?U;W@B'(<?\;9GF,-N]U?L[".-$+F1HE&P4*ST9B:D&
M@WZZ[OENZAR_.L9Q>2Y-ICPJ=[]_:![C$;[4!5>T]>A]-=BSZ1.J21>-&$?V
MZM7[Z0=MF+!DSROQV=/'SUZNFV9LVK5!^99P[=N52)IID()CG,!2@(B`:]R>
M9O)]NC&;B4BB-&9JQ7(HJ_F/38#UK2GKK:OB_P`?ROVQY]B68*![\1))]/S5
M)_AI<]Q>0+1UL<1>%O61Q_RA:J94+I$V4,DYP<J.8JWR-#A[6P),-G3FK"T<
MM4)N;NKE_,D8`"Z[)H1L38BQP-R?#6,Q_D3EV<\C9^VCFN8(U:&T`[D[R#04
M>O3MI6GK7J*Z5^3<A+POC^-X7C+B2.WN&823$GN"]WJP]*GIZ`#TZX]F>@W@
MWFOC;,6;@=S*6Y#<F6$$VFJ][V3\3N*?>K&D=%5[&RU?C8QO8Z&E()'4%%9=
M\JNT4`HJBK\VZY?.?-<)R!;7FV%BLL`9*%#;N#&AV[@VXE[?A05Z5%=)&\1\
M4RF%]WB^3:;,(I*LLJD._4"E05WZ&O73GT?)<L."G1'G:+YD2K1?-V-,6Y3Q
MS4I).ZI7I^O`7M[^2<3HO+4@JL>2E8L]L(W3\CG53;M$@,/RB.HW8<4YKYOL
M9.&)VX*XN(I7!C*`-%_<E'978$(?E4G3]!SO&/%]TO(W[LG#`Z]W<#56HB[B
MO]6WK].@AV5##8Q?53GS/;IN`!8^8N`,-0+@2^IFE/QCE:YV0$51]12.[LT<
M4Q?AY)!O\-6_R69[_+6/PD+?_GCQ-S=.M=JR,BH?]JD#59L?C"?'E[G7![Y,
MA%$"1Z`,VW\3J3%V:\NI'&G3CP?XN8Y.ZD,T<T,$X$Q_&0D6!OZR./6-(I!;
M65%NB(K$5MTL]CX!(FWBN20<`&X)FU7#QUQ.._\`+^8Y!D:#$8:]N9'8@]ID
M#O0?Z0&8]>@U./.\\UCXZQN`L6[LCDK>")0.O9VK5J'K4T%*@[G3"^7N+C!/
ML<XI=>%?6;RRN*5N.6"[\]9^!VDCD*TR++*V?)8HIE%-=)G-W:3:E.;XM8],
M!_RAJ;\5R62?QQE^>W?>OZI;JXC4G=84!AMU!H/S!%H:=6U$>0P*ISK%<3A`
M*VXACD'I[A/?*?\`<Q]3M33K7W!LU`9X[(N%'#Y_?V&-J-7*Q76]ZN$A,LH*
M!H+3,-W!O+V&2?2CIK#,BUVA4])RF9T<J?\`$*4?0VPQCX'M6P_CW,\ODM7N
M[QI)/;C`+&4Q("H``+5,C-4C4B>7KC_D.98WC$4XM;;VD[V]P1A06-=R0!1:
M$:NT.DGJA?NFS5GV[,7+IXX09,FC;+/'1=R[=N5RMVK9L@B_%5PX<KJ%(0I2
MB8YC`4-Q';6N7S/Y.13+<\3/8L?>SF&X`"_$U&VWKTVUM7Q9P&:;VH^0.\Q8
M"GZB)F+'T_-O]!I==Y])K/`OJQX@\!L;66>LB$IE5X]+.2YD&MFM,51$[!;Y
M=_+(Q0)(`L^NU[CMBD+X![90`/EUSO"U[+S;RAD^>WL44#16RM[84M&&8+&J
MCOZ&B$U/Q/II1Y1A7B/`['BV.E=C)<D=Q/WE>YF)V.^[@#?H!ZZ[9#[7J@R6
M"(NTM.4^9*]F5[C"*LB\3+Q=7=T2-OJE90EWT*\29(1M@+`HS8G;`J5X+A)(
M`4^<P>(Z9OW*WJ9MX&Q5FV)6<J*,RNR=Y4$E=NZFY``%=AK:/"%FV+%RF0NQ
MDFB[JFA0-VAB*5#4J:`U^HUD[[8+D]F/)>/N1_'O)MKG;K`83EJ+/8^D+',O
MI]]5V%Q-9XF=I;*6D55W:M<;2-6([8("?P;&<+E3`"&*4O+_`'(<7Q6*R>.S
MF-@CMY;Z)_<1!124[2'I\3W;_&F^E7@S/93(6-[A[Z1I8K.1>QV-31BU1]-N
MGIJ5EJM.I\U;NW"+1NJZ<JIH-FZ:J[E94P%31;HI'565.8?0I4TR"81_``'6
M/::<B)*EV-`!U).P`^9.L,RHI=S1`"2?IKSTNM6JP78#WAV;)%W@(RZ4.2R/
MR&Y!V6!L<6RL->D:VS6G(NDL)B,E$7D<]CTY&R1!")K$,3^"78/0-7R\DW3\
M#\)V]ACI)8,@L%M"C*[(X8J"]"A%"0&K_/5.^$6D?,/*]Q>W\<<UF))I"'7O
M4BI[10_.G\J:EN\\>)7!*E\-^3UUM?%;CZQBZ;@W)EE2D(/$=$K\XPEHNIRB
MT&YAIJ&A8^3C99*:!N+=9%4AB*^(@.JK\-Y7S:]Y;C;5,KD");Z)&1IY'5D9
MP&JK$@[$[:L5RCCG%8>/7LUQ8VH1+:1@5B52I"U4U`!KW$;_`.6HVWVJ5)GW
M_)[DED;WG98.K8%KU/E!`3%0?3EVO;&5BTU]MDUCM6M->*%`0W(*GIZ&'5B/
MW1W=LN`Q=D*&[>YD8"@JJ(E#1NN[$==09^WVWKE;^\BJMHB*O:/RDNU%J/D`
M=_EK'9<<\:NRGNZYHJ<J\GQ=$X_U-S>HUO./LF0&,5YAQBYU5<1TJ(A;%8E2
M-E??7C'3\S=(IS&22,([`(B*^/)\E\>>%\&W$K5I\S,H+`1O+19NZ<U1"-_N
MH"WRUH-E@^;>5LD_(YNW%PEU2LBH/[7]H`$]`>VOQ)KIX#$?3WT>T[*N,[?0
MN0499KS5;_3[+2ZXYY9XWLK>=ML#8(^5K<4M7&@`[GB/)EHB3Z-/YW`C[8>I
MM1-G/+WFB_Q%S9Y"Q>"PF@>.23]%*O8KBC?<S&A^9J-2;C_'OC&"^BGLIXGO
M$D5D472$]RFH%.O7J.NL@<ON476/S;Y>2G6!R^Q-:V5YHD[*QU6S7:9&MT"M
MUJV/:5%6M-"C9";VIO98Q]:8UVBV;H.&?T<@Y2(0Z:@@D(\OB7'/)?#>+#R7
MQBY3]+(!6&.KNZ`]I+Q]I6@-:_=4"OI72[D6>X1R3D3<&Y%;G]3&/M=R%&XK
M]K5!W_"NF$NVGJZXE==U*K>9^-/,2P.<@OKM%1L!B"2L]7ELC)1*Z+QR_M]<
MN6/U*_8(EI5_8(=1=VT$A_<*0BX+"0IYU\4^3^3^0;Z7!<HQ<1QGL.7G]LK$
M>@",C!E`8$UHP(`)IJ'/(?`L%PVVCRG&LBZY%I@(X2X9J_%>TBE"!Z;D_+6]
M/;?G#,</T:\$,>9ZE)=?.F?G&+WV0%YQ50MDDX:A5>1NGU-E*KXN%YI8SBOF
MD#*A[@O3F$X>8CIJ^(\+B9O.&;O<.B-A,?[RH`**LDC=E$IMVU$@7_MI33L\
MDY>]M/$V/M<BSMDKL1A^[\S``D]WTJO\=:K\B\.?]3_;4\43.4"H2>5>3\/F
M.4W3`JAOSTWRI_0U3^0`8QE*C&QX;_@00#X!KK\?RYR_[D<C[+=UO#8O`M/Z
M46/N7_2Y8?PUP<]B_P#BO"%BN_N23B4BE*ENX#\%`(TM>HFO3W8KSVQ/R$R&
MP<ML#];O&3#5'K3.7W7C2VVB4DL!40,)_<;$>O;6C-VQ80]2`S:@;8?$=:_+
M,\7COA=WQVQ->0\BRD\SD?F,4TG=Z;T[2(Q]:Z6>.HFYCR:#+W8)PN$LHXXR
M>A=%IO7:M2S;?TTUC+IK:N^8_>'D7DA(H&D8ROSO(GD*=PL!E4VX666?4FBD
M%0WD`"V0NB(I?^H-]B_#75\Q%.&^$K/C4/VW4T5I;]=Z*#*]:?'M-?F1M37,
M\;HW(_*]SF)JLD;2RD^@))`'_P`A3Y#5W.4+CAV3]YG+QMRBR9%T;CS3C7*"
M///<D0.,3RBN(FM6Q/5(6$LMC7(R,=W8&SQ^=NB4YU$4E!V`HB.D\.2Y+XY\
M'X@<5MY9L[*ZR2((FEVE[I265*'>M.H`VTHFLL!S?RMD$S\XCQ<((0^XB5:/
M[>K@GTKMIW#&/3KT:U3)>.[13>0L98KA6;S4;!4J^YY;8VL#>;LT)/L).`B5
MX!J`.9M-]+MD4Q:)_.Y\O;#U,&HIR'F#S+-BKFTNK!HK"6!TE?\`1RK1&!#5
M8L>V@.QZ#4AV'CWQ?;W\36=U&U\LJL@%U&6+`U`[0-^G3J?CK2_NULU:SYW(
M\$N,UDL4'`T;&A<8/L@2]EE&417H1*]9"->+:O*R$FX:QS!,U"IK/<RIR@85
MBE#?R`!>?ANQNL'X:SG*(HVFN;IIHXUC!+ADB[4(&[&CLQ%.FFUY,EBR_DW#
M821@D,':SLS+VT9JD&NVR@==/.]G7;!QAXQ\6<FKT7-6-,B9IN]/L-/Q-2<>
MW:`MTG^8)^.<0R5IG0KCZ1)7ZU4RO#/5G#DR15CH%02\E%`#4-^-O&'*.2\K
MM8KVPN8,1#.DLTDJ,J]@;N.S`%NX;;?&NI$YQS[!X3`7#6]W#)D)$98HXV#L
MS,.WH*TIUK\::P+]N/PPMO&;AU.96R5$/8"^\H+'#WII"RS4[6;C,8UZ*4CL
M?#+HKE*Z:O+!_4GTL")P`Q6[U`3`!Q,`./\`<'S.SY+RY,9C']S'XR,P]XZ-
M(3]]/2@HJ[>H.N3X9XQ=X#C[WU^.V[R#+(%I^5!4CYU/<>OI34AO4"ZF+28N
MM69WFGVJER+N3CXZWUN=J[]_".RL)EBRL$4[B';R(?'2<$9R;9N\,=NJ*9P3
M5`IO$=MM*+2YDLKN*\B"F6&17`(J"48,`1Z@D;CU&M-S`EU;R6TA(CD1E-#0
MT8$&A]#OM\]-N<$NH'B/UX7ZX9+P&;*3RU76FMZ))NLBW*/M*+2OHS#.=42B
M4FE<A3,W#Q_'("L<3'`Y$BAL'J(R%SORKRCR'918_.BU2VAE]P"%&2K`4%>Y
MWJ`"=MM,_BO`<%P^YDN\49FGE7M)D96H*U-.U$I7_P`M;N\C<!4;E%@_)?'[
M):U@1H>5JRXJEH5J\FE#6`D6Y7;N%1BY-9F_39N1.V*'D9%0OB(@)1`=,O`9
MF[XYFK;.V`C:\M9`Z!P60L/Z@""1]"/KISY7'6^8QLV+NNX6TR%6*T#4/P)!
M'X@ZU&X)=6?'+KMD<D2''JPYA%+*D;`1]JB+[=(RSQ!EJRO)+0TO'M&U9ASM
M)AH27<)`J*BA!25$HD^`@[.<^2\_Y!6V&>CM%:T+E#%&R'[R"P8EVJ"0-MM-
MCB7`L)PQISAVN"+@*&$C*P';6A`5%H=SN:ZT0FOMG.N:P2TK-S$SR7?R<U+2
M$Y(NE\L0:AW$E*NUWSUP;W*$;YEG+DYA_'<=/>#]Q//;:VBM(8L<(8555I#(
M*!5"CI,/0:;$_A/AMQ<274IO/?D)+$2**DFIZ1_]:_COK(.#/MX^OKC]F3&>
M<:5_WA(7'$]PB+S56MKR'#3%=-/P2HN8I64BT*:P5>MVCL"K%(59/^(F4=_3
M8>=G//'.<_@KCCUZ+(6%RG8Y2-P]#U(8RMN?B0=+,7XAXCB,A%DK7]29HG#`
M,ZLI(((J.P$BH^(UF7GMTP<.^P.U-<DY*8W.@992CFL/)9%Q=*145*6F*CR%
M2BF=PBIR&G8*>/$(AX-7(MTWB26R0K&2*0A>3P3S!S'@%F^*Q;PSXICW>U.A
M=`?4+1E(KU(J17?K6O0Y7XRXSR^Y2^OUDCOD!'N1MVL13HU0:_+H?36$N*_V
M\?`'C1?HS)LG&7S/EN@GC:2KI,T2D#*52$E&2Z;AE+)T^NU^`AY>19JI@9(9
M(KU!(WS%2`X`8.MR;SUS[D>-;$1-;V%F]0YMD,;LI%"I8LQH03TI^&VN9@/$
M/$<'=+>E9KJ=*=OO,&52#6H4`;@@==;;\\^K+C9V+OL;/.04QEML3%3"SL:J
MPQY=6-6C2C;EHA:8>R#5U79KZJ0,$&W324**?MIE$NP[Z;/`O)?(?'23K@4M
M7>Y*F1IHR['LZ;JZ>I)/S).G%RS@N$YE[/\`RQF"V]>P1LH&].H9'!Z#2GY&
M];/&_D_Q8QCP]R$6]Q>'L1J4`]/1I=D9P-C2#&]8>U*N)OY9Q"R2#PAHE^H+
MG^7(*RP^>Y1]!2<>\@9[C/*I>88\0-EYC(6]Q2R?W3W,`H932O3[MA\=;LUP
MW#Y[!1<>O/=7'PE>WL8!OL!45)5AT.^W7?7/BSUO\<^'/'G)/&S"2=YBZ;EE
M>W.[G9Y>QLI'(CQW;ZVE5'#IO9T89DFW5A(5`I(W^6,5J8!-L83&WQRCG^?Y
M?G[?D69]EKVV""-54B,"-NX?:6)W/YONW'PU[P'#\/QO#2X/&"1;6;N[F)'>
M>X=IW"J.G3[>ND+P-ZF^*?758L@VKCZ.3'$YDBNP=6G'N0K<PM!V<-`OG<DU
M;PH-*_#?0BY>N@4<";W05%)/T#Q]5_.O)_)O(4,$&>_3K';L2OM(R5)`7[NY
MWK0#;I2I^.D?%.!8/AT\USB3,9IQ1C(RGUKMVHE*GKUZ#6D5@^V@ZZ+1-3-@
MG)GDN^E9^9DY^4<JY8@S&<RDP_<R4@Y-Y4,P^:[MT<PB(B([^HCI[VG[C>?V
M,*0V\6-"(BHO]F395`4#_P"ZG0?#36E\)\.FN9+N5KPSR.6)]Q/_`%&I&T73
MZU/STN,)_;M]>N!\OXTS73PSC)6S%-S@KY5V=KR)#3%=4L%;>$D8A26BTJ8Q
M5?-FSY(BOM@LGN<A?78-M<[-^>^<Y[%7.'NUL4M;J)HW,<3JW:W6A,I`/I6A
MTMQGB'B>(R,63M#=?J(7#`,ZE20:BH]NM*CT(TM>4O0]PDY@YUOO(?,<QGMS
M?LBJPYYQ&OY)BHNN-D8&`C*W&,HF)<5"0.S9-XV)2^0RRFZ@G-O\PZ3<6\X<
MQX?@H./8:*P&/MZT[XG9F)+,2Y]T!C5CZ#:GPUNSOBGB_(LI+F,B;K]=*P)*
MR*`M%"T4%#04`K\]]?'CM]O]UK\<[TRR+%XQL^4K%$.VLC`)9IM1+M7X*39K
M`X;R36JM8F#KDB\26*4Q1D&STJ9R@8@%,`#KSR'SIY#Y#8'&2W,=K:L*-^G0
MQLP^;%F8?Z2-9POB?AV%NUO8XI+B=/R^^P<+]`%4?C73TQ$B)E`I/0H`4"E`
M"@4H%``*!0*4`*``&P`'H`:ATCN<NQ))&_S/Q^OSU)*@**+^4=!Z`?`?+7UU
MZUG1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1
'HT:-&C7_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
